

## Trofinetide

## Chemical Properties


CAS No. : 853400-76-7

Formula: C<sub>13</sub>H<sub>21</sub>N<sub>3</sub>O<sub>6</sub>

Molecular Weight: 315.32

Storage: Keep away from moisture, Store at low temperature  
 Pure form: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Trofinetide (NNZ-2566) is a synthetic analog of the endogenous N-terminus tripeptide. It has been shown to be neuroprotective in animal models of brain injury.
Targets(IC50)	Others, iGluR
In vivo	Trofinetide treatment suppresses IL-1 $\beta$ expression in the injured brain hemisphere for up to 7 days post-PBBI. Trofinetide suppresses penetrating ballistic-like brain injury-induced inflammatory cell infiltration at 3 days following PBBI as compared to vehicle treatment. All doses of Trofinetide completely suppress the delayed occurrence of NCS as compare with the vehicle-treated animals. Trofinetide treatment produces significant reductions in the injury-induced up-regulation of IL-1 $\beta$ , INF- $\gamma$ , and TNF- $\alpha$ expression. Trofinetide treatment significantly decreases the elevation of IL-6 (79%), E-selectin (81%), IL-1 $\beta$ (76%), and TNF- $\alpha$ (72%) mRNA levels in the injured hemisphere at 12 h post-PBBI, with maximal inhibition occurring between 12 h and 24 h. The high doses of Trofinetide (10 and 100 mg/kg bolus followed by continuous infusion) attenuate non-convulsive seizure (NCS) occurring beyond 2 h after permanent middle cerebral artery occlusion [1][2].

## Solubility Information

Solubility	H <sub>2</sub> O: 44 mg/mL (139.54 mM), Sonication is recommended. DMSO: 71.43 mg/mL (226.53 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	3.1714 mL	15.8569 mL	31.7138 mL
5 mM	0.6343 mL	3.1714 mL	6.3428 mL
10 mM	0.3171 mL	1.5857 mL	3.1714 mL
50 mM	0.0634 mL	0.3171 mL	0.6343 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Wei HH, et al. NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats. *J Neuroinflammation*. 2009 Aug 5;6:19.

Lu XC, et al. NNZ-2566, a glypromate analog, attenuates brain ischemia-induced non-convulsive seizures in rats. *J Cereb Blood Flow Metab*. 2009 Dec;29(12):1924-32.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481